Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Children 6-35 Months
NCT05212623Phase 1Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Quadrivalent influenza split vaccine (Changchun Sponsor Institute of Biological Products) in influenza, sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Incidence of adverse events within 7 days after each vaccination. Started Oct 2021; status: completed.
02
Drugs
Quadrivalent influenza split vaccine (Changchun Sponsor Institute of Biological Products)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05212623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212623.